This trial is active, not recruiting.

Condition degeneration articular cartilage knee
Treatment cartistem®
Phase phase 1/phase 2
Sponsor Medipost Co Ltd.
Start date November 2012
End date May 2016
Trial size 12 participants
Trial identifier NCT01733186, MP-0201-01


The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect
cartistem® human umbilical cord blood-derived mesenchymal stem cells

Primary Outcomes

Number of adverse events
time frame: 12 months

Secondary Outcomes

Improvement in IKDC score
time frame: 12 months
Improvement in knee function and pain and grade of cartilage regeneration
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients with an intended- to- treat single focal, full-thickness cartilage defect (ICRS [International Cartilage Repair Society] Grade 3 or 4) of the knee as a result of ageing, trauma, or degenerative diseases. - Age ≥ 18 years old - Size of the articular cartilage lesion is ≥ 2 cm2 - Swelling, tenderness and active range of motion ≤ Grade II - Joint pain : 20-mm - 60-mm on VAS (Visual Analog Scale) at the time of Screening - Appropriate blood coagulation, kidney and liver function laboratory parameters: PT(INR) < 1.5, APTT <1.5×control Creatinine ≤ 2.0 mg/dL Albumin ≤ trace in urine dipstick test Bilirubin ≤ 2.0 mg/dL, AST/ALT ≤ 100 IU/L - Ligament instability ≤ Grade II - Lower extremity alignment within 5 degrees of the neutral weight bearing axis - No meniscal surgery within the past 3 months and more than 5mm of meniscal rim remaining - Ability and willingness to fully participate in the post-operative rehabilitation program - Subject is informed of the investigational nature of this study, voluntarily agrees to participate in the study, and signs an IRBapproved informed consent prior to performing any of the screening procedures - Body Mass Index (BMI) ≤ 35 kg/m2 Exclusion Criteria: - Patients who have been treated previously and are asymptomatic - Avascular necrosis/ osteonecrosis - Autoimmune or inflammatory joint disease - History of infection within the past 6 weeks - Surgery or radiation therapy within the past 6 weeks - Serious medical co-morbidities, which would otherwise contraindicate surgery, as determined by the investigator - Currently pregnant or nursing - Psychotic diseases, epilepsy, or any history of such diseases - Current abuse of alcohol (> 10 drinks weekly) and/or regular exposure to other substances of abuse, currently an active smoker - Chronic inflammatory articular diseases such as rheumatoid arthritis - Enrolled in any other clinical trials within the past 4 weeks - Administered immunosuppressants such as Cyclosporin A or azathioprine within the past 6 weeks - Ligament instability > Grade II - Uncorrected significant lower extremity malalignment (i.e. > 5 degrees) - (sub-) Total meniscectomy (<5mm rim remaining) - Corticosteroid or viscosupplementation injection to the affected knee in the past 3 months - Principal investigator considers inappropriate for the clinical trial due to any reasons other than those listed above

Additional Information

Official title Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects: A Phase I/IIa Clinical Trial in Patients With Focal, Full-thickness Grade 3-4 Articular Cartilage Defects of the Knee
Principal investigator Brian J Cole, MD
Description Conventional treatment modalities have not been able to provide complete and sustained resolution of symptoms following damage to the articular cartilage. Despite the numerous techniques available today, complete healing of damaged or defective cartilage or consistent reproduction of normal hyaline cartilage does not occur, and continuous drug administration or secondary surgeries are common. Research in mesenchymal stem cells has had a rapid acceleration over the past decade and MSC-based therapy has become one of the objects of investigation for a new branch of medicine termed regenerative medicine. This emerging technology shows great promise for producing transplantable cartilage constructs to restore the function of degenerated joints. CARTISTEM®, a combination of human umbilical cord blood-derived mesenchymal stem cells and sodium hyaluronate, is intended to be used as a single-dose cellular therapeutic agent for cartilage regeneration in human subjects with cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
Trial information was received from ClinicalTrials.gov and was last updated in June 2015.
Information provided to ClinicalTrials.gov by Medipost Co Ltd..